Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VAC 85135

Next Previous
Drug Profile

VAC 85135

Alternative Names: VAC-85135

Latest Information Update: 10 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nouscom
  • Developer Bristol-Myers Squibb; Janssen Research & Development
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Myeloproliferative disorders

Most Recent Events

  • 13 Jul 2022 Phase-I clinical trials in Myeloproliferative disorders (Combination therapy) in USA (IM) (NCT05444530)
  • 06 Jul 2022 Janssen Research & Development in collaboration with Bristo Myers Squibb plans a phase I trial for Myeloproliferative disorders (Combination therapy) in USA, Canada and Spain (IM, IV) (NCT05444530)
  • 17 May 2022 VAC 85135 licensed to Janssen Research & Development

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top